Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial
Authors: F Ang, W Rapattoni, H S Bajaj, G B J Mancini, P Poirier, A Sharma, N C Wong, A Slee, A Levin, K W Mahaffey